Cargando…
What Is the Minimum Clinically Important Change in Negative Symptoms of Schizophrenia? PANSS Based Post-hoc Analyses of a Phase III Clinical Trial
INTRODUCTION: Minimum clinically important difference (MCID) is a measure that defines the minimum amount of change in an objective score of a clinical test that must be reached for that change to be clinically noticeable. We aimed to find the MCID for patients with predominantly negative symptoms o...
Autores principales: | Czobor, Pál, Sebe, Barbara, Acsai, Károly, Barabássy, Ágota, Laszlovszky, István, Németh, György, Furukawa, Toshi A., Leucht, Stefan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9083222/ https://www.ncbi.nlm.nih.gov/pubmed/35546918 http://dx.doi.org/10.3389/fpsyt.2022.816339 |
Ejemplares similares
-
Linking PANSS negative symptom scores with the Clinical Global Impressions Scale: understanding negative symptom scores in schizophrenia
por: Leucht, Stefan, et al.
Publicado: (2019) -
Safety and Tolerability of Cariprazine in Patients with Schizophrenia: A Pooled Analysis of Eight Phase II/III Studies
por: Barabássy, Ágota, et al.
Publicado: (2021) -
Cariprazine Safety in Adolescents and the Elderly: Analyses of Clinical Study Data
por: Szatmári, Balázs, et al.
Publicado: (2020) -
Disentangling the symptoms of schizophrenia: Network analysis in acute phase patients and in patients with predominant negative symptoms
por: Demyttenaere, Koen, et al.
Publicado: (2021) -
Cariprazine, A Broad-Spectrum Antipsychotic for the Treatment of Schizophrenia: Pharmacology, Efficacy, and Safety
por: Laszlovszky, István, et al.
Publicado: (2021)